DEF 14A: Cardio Diagnostics Holdings Seeks Stockholder Approval for Reverse Stock Split, Share Issuance, and Director Elections

Cardio Diagnostics Holdings is holding its annual meeting to vote on key proposals including a reverse stock split, future share issuance, director elections, and auditor ratification.

Summary

• Cardio Diagnostics Holdings, Inc. is soliciting proxies for its annual meeting of stockholders to be held virtually on November 15, 2024.
• The proposals include the election of seven director nominees, approval to amend the company's certificate of incorporation to effect a reverse stock split (between 1-for-5 and 1-for-40), approval of future issuance of common stock or convertible securities equal to 20% or more of the outstanding common stock, and ratification of the appointment of Prager Metis CPAs LLC as the company's independent registered public accounting firm for the fiscal year ended December 31, 2023.
• The board of directors recommends voting FOR all proposals.
• The record date for determining stockholders eligible to vote at the annual meeting is September 24, 2024, with 25,905,656 shares of common stock outstanding as of that date.
• The company has engaged Sodali & Co. as its solicitation agent, agreeing to pay a fee of $15,500 plus disbursements.
• The company is an emerging growth company and may take advantage of exemptions from various reporting requirements.
• Stockholders can vote online during the annual meeting or in advance by proxy through the internet or by mail.
• The company is seeking approval for a reverse stock split to maintain its Nasdaq listing, as it received a notification from Nasdaq that its stock price was below $1.00 for 30 consecutive trading days.
• The company is also seeking approval for the future issuance of shares of common stock or securities convertible into common stock equal to 20% or more of its outstanding common stock in a non-public transaction, with a maximum aggregate dollar amount of $10.0 million and a maximum discount to market of 25%.
• The company's executive officers are Meeshanthini V. Dogan (CEO), Elisa Luqman (CFO), and Robert Philibert (Chief Medical Officer).
• Warren Hosseinion serves as the Non-Executive Chairman of the Board.
• The company's audit committee consists of Paul F. Burton, James Intrater, and Oded Levy.
• The company has adopted a compensation recovery policy (clawback policy) effective October 2, 2023.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is taking steps to address its financial challenges and maintain its Nasdaq listing, the need for a reverse stock split and potential share issuance indicates underlying financial difficulties. The board's recommendations and corporate governance efforts provide some positive aspects.

Positives

• The company is taking proactive steps to maintain its Nasdaq listing by proposing a reverse stock split.
• The company is seeking flexibility to raise capital through the potential issuance of shares or convertible securities.
• The board of directors is actively engaged in corporate governance, including risk oversight and the implementation of a compensation recovery policy.
• The company has a diverse board of directors, with representation from women and underrepresented minorities.
• The company is offering stockholders a virtual meeting format to increase accessibility.

Negatives

• The company's stock price falling below $1.00 triggered the need for a reverse stock split proposal.
• The potential issuance of shares or convertible securities could dilute existing stockholders' ownership.
• The company's reliance on the ATM Agreement and the need for additional capital raise may indicate financial challenges.

Risks

• The reverse stock split may not increase the stock price over the long term and could decrease liquidity.
• The potential issuance of shares could dilute existing stockholders' ownership and have an anti-takeover effect.
• Failure to obtain stockholder approval for the reverse stock split or share issuance could negatively impact the company's ability to maintain its Nasdaq listing and raise capital.
• The company's ability to continue as a going concern is dependent on raising additional capital and satisfying near-term debt obligations.

Future Outlook

The company is seeking to maintain its Nasdaq listing and raise additional capital to support its operations and meet its short-term liquidity requirements.

Management Comments

• On behalf of the Board, we would like to thank you for your support of Cardio Diagnostics Holdings, Inc.
• The Board currently intends to effect the 2024 Reverse Stock Split, if necessary, in order to regain compliance with the Minimum Bid Price Requirement.

Industry Context

The company operates in the cardiovascular diagnostics industry, which is characterized by technological advancements and increasing demand for personalized and precise healthcare solutions.

Comparison to Industry Standards

• Many companies facing similar listing compliance issues on Nasdaq or NYSE have pursued reverse stock splits, including companies like Ocugen Inc. and CytoSorbents Corporation.
• The proposed terms for the future issuance of shares, including the maximum discount of 25%, are within the typical range for non-public offerings by companies in similar financial situations.
• The executive compensation structure, including base salaries and potential bonuses, is generally aligned with industry standards for companies of similar size and stage of development.

Corporate Governance

Related Party Transactions

• Meeshanthini Dogan and Robert Philibert will benefit from the University of Iowa Research Foundation's Inventions Policy, which entitles inventors to 25% of income from earnings from their inventions.
• Timur Dogan, spouse of Meeshanthini Dogan, has been a full-time employee of the Company since August 2019.
• Dr. Stanley Lau provides advisory services for which he has been compensated through the issuance of restricted stock units (RSUs).

Stakeholder Impact

• Stockholders may experience dilution if the company issues additional shares.
• The reverse stock split could affect the liquidity and trading costs of stockholders' shares.
• The company's ability to maintain its Nasdaq listing and raise capital is crucial for its long-term viability and the value of stockholders' investments.
• Employees' compensation and benefits are subject to the company's financial performance and the implementation of the compensation recovery policy.

Next Steps

• Stockholders will vote on the proposals at the Annual Meeting on November 15, 2024.
• The board of directors will determine whether to implement the reverse stock split and at what ratio.
• The company may pursue a non-public capital raising transaction if the share issuance proposal is approved.

Key Dates

Keywords

reverse stock split, proxy statement, annual meeting, share issuance, director election, Nasdaq, corporate governance, compensation, Cardio Diagnostics, stockholders